Background: The serotonin precursor 5-hydroxy-L-[β-
Background
Non-invasive assessment of the serotonergic biosynthesis by 5-hydroxy-L-[β- 11 C]tryptophan ([ 11 C]HTP) is an established PET marker for many forms of neuroendocrine tumors (NETs) [1] and has recently been suggested as a surrogate marker for the neuroendocrine pancreas [2] [3] [4] .
Di Gialleonardo et al. showed that [ 11 C]HTP accumulation in a pancreatic neuroendocrine cell line was significantly increased by blocking the major route of degradation, monoamine oxidase-A (MAO-A) [2] . Furthermore, this mode of degradation was not present in a ductal cell line. The authors therefore posit that an HTP analogue, following the formation of 5-hydroxy-[ 
]5-HT) by aromatic amino acid decarboxylase (AADC), resistant to MAO-A-mediated degradation will have an increased retention in neuroendocrine tissues containing the amine precursor uptake and decarboxylation (APUD) mechanism. APUD cells include not only the islets of Langerhans in the pancreas but in a broader scope also many forms of NETs. In fact, [ 11 C]HTP-PET was originally developed for assessment of the AADC step in serotonin biosynthesis but has found extensive use as a highly sensitive diagnostic tool for primary or metastatic NETs [1] . However, the contrast to surrounding tissues and hence the sensitivity are affected by the rapid MAO-A-mediated conversion of [ . Current strategies to improve contrast involve peroral administration of the AADC inhibitor carbidopa, which increases the biological half-life of the tracer by reducing peripheral metabolism, e.g., in the liver. However, this method induces large individual variations in tracer metabolism and precludes comparison between examinations and therefore therapy efficacy monitoring [5] . Increased retention of [ 11 C]HTP in NETs could improve the sensitivity of examination in addition to potentially visualizing smaller NETs currently below detection threshold.
Development of new HTP analogues with improved resistance to MAO-A degradation and with retained affinity to AADC is a difficult challenge [6] . A straightforward approach to potentially alter metabolic stability while retaining [ 11 C]HTP structurally congruent to biogenic HTP is to isotopically substitute the compound with deuterium in a position that would induce a kinetic isotope effect (KIE) large enough to deter MAO-A interaction. Similar approaches have previously been employed to improve pharmacodynamics properties of radiotracers and to increase metabolic stability against unwanted degradation which impairs visualization of a target tissue [7] [8] [9] .
Deuterium substitution at the β-carbon adjacent to the reaction center involved in the deamination pathway would typically be expected to give a minor KIE of 1.1 to 1.2. While this effect would not be expected to be particularly strong, the β-position was predicted to be readily accessible for 11 C-and 2 H-labeling by only minor changes to the original synthesis of [
11 C]HTP, and thus, it would serve as a convenient test case to explore the means of deuteration to improve MAO-A resistance. A more potent position could be deuteration at the α-carbon, which is expected to yield a primary isotope effect that is significantly higher than the secondary KIE. However, this would require that the deuterium label in α-position remain intact also after conversion by AADC to 5-HT, which is uncertain. [1-N-11 C, α,α-2 H 2 ] L-deprenyl, a selective MAO-B inhibitor, has previously been reported to induce a KIE of 3.8 ± 1.1 in baboon brain [9] .
Here, we present the radiosynthesis of 5-hydroxy-L-[β- 11 [11] .
Purification was performed by semi-preparative highperformance liquid chromatography (VWR LaPrep HPLC, VWR, Radnor, PA, USA) using an Ultrasphere ODS column (Beckman, Brea, CA, USA, 5 μm, 250 × 10 mm) with eluents A: acetic acid (17 mM)/ascorbic acid (1 mM), and B: ethanol (99.5%). After purification, the eluents were removed using rotary evaporation and the product was reformulated in 10 mL pharmaceutical-grade solution containing ethanol 99.5%/phosphate buffer/water (0. After incubation, the cells were filtered using washing buffer Tris-HCl (50 mM, pH 7.4) through a Whatman GF/C filter paper (pore size 1.2 μm; Semat International Ltd., St. Albans, UK), using a cell harvester (Brandel, Gaithersburg, MD, USA). The radioactivity of the cells trapped on the filter was measured in a NaI (Tl) well counter (Uppsala Imanet AB, Uppsala, Sweden), and the cellular radioactive uptake was corrected for radioactive decay. Radioactive uptake was expressed as percent of incubation dose (%ID) per million cells.
Ex vivo organ distribution in rats
Sprague Dawley rats (n = 26, weighing 392 ± 68 g) were housed under standard laboratory conditions with free access to food and water. All handling and experiments were carried out in accordance with the national guidelines and were approved by the local ethics committee for animal research. All applicable institutional and/or national guidelines for the care and use of animals were followed.
Rats under general isoflurane anesthesia (3.6%) were administered with 12.0 ± 2.1 MBq The animals were allowed to wake up following tracer administration and were euthanized by CO 2 30 or 60 min following injection. Tissues of interest were immediately excised, and the radioactivity concentrations were measured in a NaI (Tl) well counter and related to the administered amount of tracer and the animal weight by standardized uptake values (SUV) to allow for comparison between animals.
Cynomolgus PET/CT
The non-human primate experiments were carried out in accordance with the national guidelines and were approved by the local ethics committee for animal research. All applicable institutional and/or national guidelines for the care and use of animals were followed. Cynomolgus monkeys (n = 2, 7,000 and 8,900 g) were examined in this study. Anesthesia was performed as described previously [3] . The results of the [ Venous blood samples (0.2 mL) were collected at 0.5, 1, 3, 5, 10, 15, 20, 30, 45, 60, and 90 min after each injection to measure the radioactivity concentration in whole blood and plasma. Blood samples (1.5 to 2.5 mL) were drawn at 5, 30, and 60 min following tracer administration for analysis of tracer metabolites in plasma.
Tracer metabolite analysis of [ 11 C]DHTP and [
C]HTP
The blood sample was centrifuged at 4,000 rpm for 2 min at 4°C (Beckman Allegra X-22R Centrifuge, Beckman Coulter Inc., Palo Alto, CA, USA). One milliliter of plasma was taken and 1.0 mL of 7 w/v % perchloric acid was added to precipitate the proteins. The mixture was centrifuged at 13,200 rpm at 4°C for 1 min (Eppendorf 5415R centrifuge, Eppendorf AG, Hamburg, Germany). The supernatant was filtered through a 0.2-μm nylon membrane (Corning Incorporated, Corning, NY, USA) by centrifugation at 13,200 rpm at 4°C for 1 min. Ten microliters of unlabeled 1 mg/mL HTP, HIAA, and serotonin (5-HT) was added to the supernatant. The parent compound and metabolites were separated by HPLC and fractionated based on the UV signals from the added unlabeled compounds. The percentage intact tracer was then assessed by measuring the activity in each fraction using a NaI (Tl) well counter (Uppsala Imanet AB) and correcting for radioactive decay. The sample preparation recovery was determined by measuring the radioactivity in the plasma, filters, and the pellet.
Image analysis
Image acquisition was performed in three-dimensional (3D) mode and reconstructed using an iterative OSEM VUEPOINT algorithm (2 iterations/21 subsets, in a 128 × 128 matrix, zoom 50 cm in diameter). Reconstructed data were analyzed by PMOD (PMOD Technologies Ltd., Zurich, Switzerland). Regions of interest (ROIs) were delineated on co-registered transaxial CT slices. Entire organs, when possible, were delineated on sequential slices and combined into VOIs. Organ uptake was expressed as SUV.
Statistics
Results are expressed as averages ± standard deviation throughout. Comparison between groups was assessed by Student's t-test. For the cell experiments, the linear regression curves and subsequent comparisons in elevation and slope were performed in GraphPad Prism 5 (GraphPad, La Jolla, CA, USA). P < 0.05 was considered significant. Negligible uptake (unaffected by inhibition of AADC or MAO-A or by competition by unlabeled HTP) was seen of either isotopologue in non-neuroendocrine PANC1 cells (data not shown).
Results

Radiochemistry
Ex vivo organ distribution in rats
There was a moderate increase in pancreatic uptake (17% at 30 min and 40% at 60 min) of [ 
Cynomolgus PET/CT
We have previously shown that pancreatic uptake of (Table 1) . MAO-A inhibition increased the percentage of intact radiotracer in plasma compared to baseline, but again there was no statistical difference between the isotopologues.
Discussion
Improved resistance to MAO-A will potentially yield markedly increased intracellular retention of [ 11 C]HTP in neuroendocrine tissues. [ 11 C]HTP is currently used as a universal diagnostic imaging biomarker for benign and malignant NETs [1] . However, a higher amount of intact [ 11 C]HTP in plasma has been shown to improve the tracer uptake in NETs, and patients therefore are premedicated with the AADC inhibitor 100 to 200 mg carbidopa orally 1 h prior to the PET examination [5] . This procedure not only improves sensitivity but also introduces a new parameter that directly influences absolute uptake in lesions: the individual time for gastrointestinal absorption of carbiodopa. Additionally, the time from ingestion of carbidopa until PET examination can be variable in case of delays in radiochemistry. This taken together makes direct quantitative comparison between examinations -even repeated scans within an individual -impossible or difficult. Importantly, it precludes the possibility of quantitatively monitoring treatment efficacy by using SUVs in individual lesions. One could consider to induce an increase in retention of [ 11 C]HTP in NETs as seen in the endocrine pancreas in Figures 3 and 4 by pre-treating patients with a clinically approved MAO-A inhibitor such as moclobemide. This would likely improve sensitivity substantially, but peroral administration would introduce similar individual variation to that in carbidopa. Intravenous administration on a routine basis is counter-indicated due to the risk of causing serotonergic syndrome due to elevated 5-HT levels in the CNS. Theoretically, development of non-brain-penetrant MAO-A inhibitors could potentially provide an alternative way forward, but we instead suggest minimal re-design of the biomarker itself to achieve the same goal in an elegant manner.
The modification to the previously published [ H. Generally, labeling using deuterated methyl iodide is expected to give higher incorporation of deuterium in the final product [12] , but in this case, the reversible enzymatic reaction from pyruvate to hydroxytryptophan is suspected to induce loss of deuterium label. The degradative process that transforms 5-hydroxy-L-tryptophan back to pyruvate proceeds over α-aminoacrylate, the same enzyme-bound intermediate as in the synthetic process [13] . The reversibility allows addition of After these promising results in cells, we investigated the biodistribution of [
11 C]DHTP in rodents and especially the effect of inhibition of MAO-A. Increased resistance to MAO-A should in theory result in increased retention in tissues, which facilitates serotonin to a high degree (i.e., the neuroendocrine pancreas in this study). We found a tendency for increased pancreatic uptake of the deuterated isotopologue, but this was not a significant change. [ 11 C]DHTP retention in the pancreas was still markedly increased by inhibition of MAO-A, but to a lesser degree than [
11 C]HTP. These results show that the current formulation of [
11 C]DHTP is less sensitive to, but still to a considerable extent metabolized by, MAO-A in rodents. Given that only 25% of the [ 11 C] DHTP was deuterated and still increased retention by 17% to 40%, we estimate that a formulation of 100% deuterated [
11 C]DHTP would improve the retention in rodent pancreas by approximately 70% to 160%. More substantial resistance against MAO-A, which may be reached by deuteration at the α-position, potentially increases the absolute uptake by up to threefold after 30 min and almost tenfold after 60 min (as seen when inducing complete inhibition of MAO-A by clorgyline, Figure 3 ).
In non-human primates, however, there was no measurable difference between [ PET imaging measurement data will invariably have lower sensitivity and more noise than data acquired by well counter measurements (in this case, ex vivo organ distribution studies and in vitro cell studies). This is conceivably one of the reasons for the lack of measurable effect in non-human primates despite promising in vitro and small-animal in vivo results.
As we did not see any noticeable increased endocrine retention of tracer in the PET study in non-human primates -most likely the most predictable for the clinical situation -we decided against further evaluation in a neuroendocrine xenograft mouse model since it conceivably could yield 'false' positive results in small-animal PET imaging and ex vivo organ distribution studies, which would not translate to imaging using less sensitive clinical PET scanners.
We conclude that the present formulation of [ 11 C] DHTP (22.1% ±4.7% deuterated) is still to a major extent degraded by MAO-A in non-human primates and that the secondary KIE introduced by a partial deuteration of the β-position has only a minor effect on the stability of [ 11 C]DHTP against this enzyme despite promising results in cells and in rodents. The small effect is likely due to the low proportion of deuterated molecules, and it follows that increasing the deuteration efficiency at the β-position, or direct labeling of the α-position, may yield improved MAO-A resistance. RKS performed and analyzed the cell experiments. GA designed the radiochemistry. LJ conceived the study. OE conceived the study and designed, performed, and analyzed the biological evaluation experiments. All authors read and approved the final manuscript.
